rebeccamycin


Also found in: Wikipedia.

rebeccamycin

Oncology An anticancer antibiotic and topoisomerase I inhibitor which may be of use in managing CA of the gallbladder. See Daunomycin.
References in periodicals archive ?
Long has enjoyed a distinguished career at Bristol-Myers Squibb where his research focused primarily on identifying the mechanisms of action of novel natural products identified as having anticancer activities, which included elsamycin, gilvocarcin, eleutherobin, esperamicin, rebeccamycin, a rebeccamycin analog, and epothilone.
announces that safety and activity data presented at the 2003 annual meeting of the American Society of Clinical Oncology (ASCO) from a Phase 2 trial in 33 patients with bile duct tumors (gall bladder tumors and cholangiocarcinomas) treated with the DEAE- rebeccamycin analogue (XL119), showed encouraging results relative to overall survival and progression free survival (alive without progressive disease, i.
These activities included: completing regulatory toxicology testing of XL784 and successfully filing the IND application at the end of the quarter; advancing a new series of development candidates and back-up compounds into preclinical testing in anticipation of filing additional IND applications; manufacturing of those compounds to support preclinical studies; building additional infrastructure in clinical development to support an expanding clinical pipeline; and completion of the manufacturing of XL119, our rebeccamycin analogue, to support initiation of registration trials later in 2003.
celeptium, distamycin A, brostallicin, duocarmycin, CC-1065 analogs, KW-2189, elsamitrucin, enediynes (calicheamicin, C-1027, lidamycin, neocarzinostatin), geldanamycin/ansamycin analogs (17-AAG, 17-DMAG, CNF-101), indolocarbazole antibiotics (CEP-701, DEAE rebeccamycin, J-107088, PKC412, UCN-01, etc.
The increase in consulting costs is associated with the manufacturing of the rebeccamycin analog to ensure adequate clinical supply, costs associated with data analysis of the ongoing NCI-sponsored phase II trials and planning for the implementation of pivotal trials in the first half of 2003.
National Cancer Institute (NCI) suggest that this rebeccamycin analogue may be safely administered and may result in tumor shrinkage in patients with bile duct tumors.
The increase in consulting costs is associated with the manufacturing of the rebeccamycin analog to ensure adequate clinical supply and planning for the implementation of pivotal trials in the first half of 2003.
Full-Year Highlights -- A major achievement in 2001 was the establishment of a broad new research collaboration with Bristol-Myers Squibb to discover a new generation of cancer drugs, which provided for alternate selection of promising targets identified in Exelixis' target validation program, as well as a royalty-free license to a Phase II cancer compound, DEAE rebeccamycin.
As part of the agreement, Exelixis has received an exclusive worldwide license to develop and commercialize a specific analogue of the Bristol-Myers Squibb anticancer compound, DEAE Rebeccamycin, which has completed Phase I safety trials and is currently in Phase II clinical trials with the National Cancer Institute.
received royalty-free rights to DEAE rebeccamycin, a cancer compound in
His experience will be invaluable in achieving smooth integration of the clinical development of our new Phase I/II rebeccamycin analogue and in the rapid advancement of our proprietary programs that are nearing the development stage.
The company filed the registration statement to gain additional flexibility in accessing capital markets for general corporate purposes, including the continued development and manufacturing of the recently acquired rebeccamycin analogue in ongoing Phase I and I/II cancer studies, expansion of drug discovery capabilities and other corporate purposes.